Veracyte raises 2026 total revenue guidance to $590 mln-$596 mln, up from $582 mln-$592 mln.
Company raises 2026 testing revenue guidance to $576 mln-$582 mln, up from $570 mln-$580 mln.
Veracyte continues to expect adjusted EBITDA margin to be greater than 26%.
Overview
Cancer diagnostics firm's Q2 revenue rose 15% yr/yr, beating analyst expectations.
Adjusted EPS for Q2 increased from prior year, supported by higher testing revenue and margins.
Company launched two new cancer tests and raised 2026 revenue guidance.
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell".
The average consensus recommendation for the biotechnology & medical research peer group is .
VCYT•
